Sökning: WFRF:(van Gilst Wiek H.) >
Fibrosis Marker Syn...
-
Tromp, JasperUniversity of Groningen, Netherlands
(författare)
Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction
- Artikel/kapitelEngelska2014
Förlag, utgivningsår, omfång ...
-
American Heart Association,2014
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-108809
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-108809URI
-
https://doi.org/10.1161/CIRCHEARTFAILURE.113.000846DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background-Syndecan-1 is a member of the proteoglycan family involved in cell-matrix interactions. Experimental studies showed that syndecan-1 is associated with inflammation in acute myocardial infarction and remodeling. The goal of this study was to explore the role of syndecan-1 in human heart failure (HF). Methods and Results-We analyzed plasma syndecan-1 levels in 567 patients with chronic HF. Primary end point was a composite of all-cause mortality and rehospitalization for HF at 18 months. Mean age was 71.0 +/- 11.0 years, 38% was women, and mean left ventricular ejection fraction was 32.5 +/- 14.0%. Median syndecan-1 levels were 20.1 ng/mL (interquartile range, 13.9-27.7 ng/mL). Patients with higher syndecan-1 levels were more often men, had higher N-terminal probrain-type natriuretic peptide levels, and worse renal function. Multivariable regression analyses showed a positive correlation between syndecan-1 levels and markers of fibrosis and remodeling but no correlation with inflammation markers. Interaction analysis revealed an interaction between left ventricular ejection fraction and syndecan-1 (P=0.047). A doubling of syndecan-1 was associated with an increased risk of the primary outcome in patients with HF with preserved ejection fraction (hazard ratio, 2.10; 95% confidence interval, 1.14-3.86; P=0.017) but not in patients with HF with reduced ejection fraction (hazard ratio, 0.95; 95% confidence interval, 0.71-1.27; P=0.729). Finally, syndecan-1 enhanced risk classification in patients with HF with preserved ejection fraction when added to a prediction model with established risk factors. Conclusions-In patients with HF, syndecan-1 levels correlate with fibrosis biomarkers pointing toward a role in cardiac remodeling. Syndecan-1 was associated with clinical outcome in patients with HF with preserved ejection fraction but not in patients with HF with reduced ejection fraction.
Ämnesord och genrebeteckningar
-
fibrosis; heart failure; prognosis; syndecan-1
-
SOCIAL SCIENCES
-
SAMHÄLLSVETENSKAP
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
van der Pol, AtzeUniversity of Groningen, Netherlands
(författare)
-
Klip, IJsbrand T.University of Groningen, Netherlands
(författare)
-
de Boer, Rudolf A.University of Groningen, Netherlands
(författare)
-
Jaarsma, TinyLinköpings universitet,Hälsa, Aktivitet, Vård (HAV),Filosofiska fakulteten(Swepub:liu)tinja77
(författare)
-
van Gilst, Wiek H.University of Groningen, Netherlands
(författare)
-
Voors, Adriaan A.University of Groningen, Netherlands
(författare)
-
van Veldhuisen, Dirk J.University of Groningen, Netherlands
(författare)
-
van der Meer, PeterUniversity of Groningen, Netherlands
(författare)
-
University of Groningen, NetherlandsHälsa, Aktivitet, Vård (HAV)
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Circulation Heart Failure: American Heart Association7:3, s. 457-U1191941-32891941-3297
Internetlänk
Hitta via bibliotek
Till lärosätets databas